Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.7.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Operating Activities:    
Net loss $ (6,266) $ (10,596)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on warrants [note 4 and note 5 [f]] (118) (134)
Depreciation 130 103
Stock-based compensation [note 5 [c] and note 5 [d]] 423 1,387
Restructuring gain [note 8] (107)  
Changes in operating assets and liabilities:    
Interest receivable 32 64
Amounts receivable 237 (293)
Prepaid expenses and other assets 647 714
Accounts payable (1,888) (784)
Accrued liabilities other (1,279) (19)
Accrued clinical liabilities (3,365) (2,263)
Accrued compensation 66 61
Accrued litigation settlement [note 7]   1,375
Lease obligation (38) (16)
Deferred collaboration revenue [note 3]   (5,040)
Net cash used in operating activities (11,526) (15,441)
Financing Activities:    
Taxes paid related to net share settlement of equity awards (22)  
Net cash used in financing activities (22)  
Investing Activities:    
Purchase of investments (4) (29,111)
Proceeds from maturities of investments 10,234 20,858
Purchase of property and equipment (1) (35)
Net cash provided by (used in) investing activities 10,229 (8,288)
Effect of exchange rate changes on cash 2  
Net increase (decrease) in cash and cash equivalents (1,317) (23,729)
Cash and cash equivalents at beginning of period 15,233 34,310
Cash and cash equivalents at end of period $ 13,916 $ 10,581